PharmaPhorum: "Merck funds Antidote’s clinical trial matching tech"
PharmaPhorum covered how our latest funding round will allow us to expand our reach and impact. The article reads:
"Clinical trial matching platform Antidote has raised $11 million in its latest funding round, led by Merck Global Health Innovation (GHI).
Founded in 2011 under the name TrialReach, Antidote looks to tackle the problem of clinical trial participation by linking up patients with researchers.
Its core solution, Antidote Match, effectively works as a clinical trial search engine, allowing the general public to search for a clinical trial they or a family member may want to participate in.
The platform is currently used in over 180 online patient communities, including the Lung Cancer Alliance, Healthline and the Juvenile Diabetes Research Fund, and is part of the Cancer Moonshot project.
So far, Match has made 14,000 clinical trials matchable whilst full coverage of US trials is a company objective for next year."
Read more at PharmaPhorum.